

FOR IMMEDIATE RELEASE

Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

SEAN EKINS, PH.D. JOINS GENEGO AS VICE PRESIDENT OF COMPUTATIONAL BIOLOGY

St, Joseph, Michigan, February 23, 2003 — GeneGo today announced that Sean Ekins, Ph.D. joined the Company as the Vice President for Computational Biology. Dr. Ekins is a world renowned scientist in the area of in vitro and computational ADME and toxicity, an important area of pharmaceutical drug discovery and development. Prior to GeneGo, Dr. Ekins held various research positions at Eli Lilly, Pfizer and was most recently Associate Director, Computational Drug Discovery at Concurrent Pharmaceuticals. He has authored over 50 peer reviewed articles, book chapters, reviews as well as several patents relating to computational and screening technologies. Dr. Ekins is also on the editorial boards of several journals. Dr. Ekins earned his Ph.D. from The University of Aberdeen.

“We are happy to welcome Dr. Ekins to our team. In addition to his outstanding research record, he brings invaluable hands-on expertise at leading drug companies” said Dr. Tatiana Nikolskaya, President & CSO of GeneGo. “Sean will lead our program in ADME/Tox, namely development of MetaDrug™, a systems biology platform for early prediction of metabolic fate and human toxicity of novel drug molecules”.

“I am very excited to join GeneGo” said Dr. Ekins, “I was attracted by GeneGo’s unique approach to Systems Reconstruction technology which links human metabolism with regulation and chemistry. We will leverage this valuable technology in a very novel product in the ADME/Tox area. MetaDrug™ will be capable of analysis of multiple types of pre-clinical data for making reliable compound selection decisions in early lead discovery”.

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s first product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. MetaCore™ integrates all levels of cellular functionality - from membrane receptors to signal transduction, transcription factors, and effector networks and is based on the proprietary database of curated functional pathways and networks.

MetaCore™ and MetaDrug™ are the trademarks of GeneGo, Inc.